10 K: a large-scale prospective longitudinal study in Israel.
Biobank
Clinical cohort study
Journal
European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
21
02
2021
accepted:
16
04
2021
pubmed:
17
5
2021
medline:
15
12
2021
entrez:
16
5
2021
Statut:
ppublish
Résumé
The 10 K is a large-scale prospective longitudinal cohort and biobank that was established in Israel. The primary aims of the study include development of prediction models for disease onset and progression and identification of novel molecular markers with a diagnostic, prognostic and therapeutic value. The recruitment was initiated in 2018 and is expected to complete in 2021. Between 28/01/2019 and 13/12/2020, 4,629 from the expected 10,000 participants were recruited (46 %). Follow-up visits are scheduled every year for a total of 25 years. The cohort includes individuals between the ages of 40 and 70 years. Predefined medical conditions were determined as exclusions. Information collected at baseline includes medical history, lifestyle and nutritional habits, vital signs, anthropometrics, blood tests results, Electrocardiography, Ankle-brachial pressure index (ABI), liver US and Dual-energy X-ray absorptiometry (DXA) tests. Molecular profiling includes transcriptome, proteome, gut and oral microbiome, metabolome and immune system profiling. Continuous measurements include glucose levels using a continuous glucose monitoring device for 2 weeks and sleep monitoring by a home sleep apnea test device for 3 nights. Blood and stool samples are collected and stored at - 80 °C in a storage facility for future research. Linkage is being established with national disease registries.
Identifiants
pubmed: 33993378
doi: 10.1007/s10654-021-00753-5
pii: 10.1007/s10654-021-00753-5
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1187-1194Informations de copyright
© 2021. Springer Nature B.V.
Références
Diabetes Prevention Program Research Group. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.
doi: 10.1016/S0140-6736(09)61457-4
Knoops KTB, de Groot LCPGM, Kromhout D, Perrin A-E, Moreiras-Varela O, Menotti A, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292:1433–9.
doi: 10.1001/jama.292.12.1433
Shilo S, Rossman H, Segal E. Axes of a revolution: challenges and promises of big data in healthcare. Nat Med. 2020;26:29–38.
doi: 10.1038/s41591-019-0727-5
Kinkorová J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation: Overview. EPMA J. 2015;7:4.
doi: 10.1186/s13167-016-0053-7
Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555:210–5.
doi: 10.1038/nature25973
UK Biobank: Protocol for a large-scale prospective epidemiological resource avilable at https://www.ukbiobank.ac.uk/learn-more-about-ukbiobank/about-us (accessed 23 July, 2020).
Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352:544–5.
doi: 10.1126/science.aad9358
Halfvarson J, Brislawn CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004.
doi: 10.1038/nmicrobiol.2017.4
Pang KP, Gourin CG, Terris DJ. A comparison of polysomnography and the WatchPAT in the diagnosis of obstructive sleep apnea. Otolaryngol Head Neck Surg. 2007;137:665–8.
doi: 10.1016/j.otohns.2007.03.014
Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148:1258–70.
doi: 10.1016/j.cell.2012.01.035
Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133–63.
doi: 10.1002/sim.3034
Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758–64.
doi: 10.1093/aje/kwv254
Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Commun Health. 2006;60:578–86.
doi: 10.1136/jech.2004.029496
Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–60.
doi: 10.1038/ng.3314
Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am J Epidemiol. 2017;186:1026–34.
doi: 10.1093/aje/kwx246
Swanson JM. The UK Biobank and selection bias. Lancet. 2012;380:110.
doi: 10.1016/S0140-6736(12)61179-9
Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163:1079–94.
doi: 10.1016/j.cell.2015.11.001
Zeevi D, Korem T, Godneva A, Bar N, Kurilshikov A, Lotan-Pompan M, et al. Structural variation in the gut microbiome associates with host health. Nature. 2019;568:43–8.
doi: 10.1038/s41586-019-1065-y
Bar N, Korem T, Weissbrod O, Zeevi D, Rothschild D, Leviatan S, et al. A reference map of potential determinants for the human serum metabolome. Nature. 2020;588:135.
doi: 10.1038/s41586-020-2896-2